Galectin-1 and immune suppression during radiotherapy

Clinical Cancer Research

Volumn 20, Issue 24, 2014, Pages 6230-6232

  Welsh, James W ^a   Seyedin, Steven N ^a   Cortez, Maria Angelica ^a   Maity, Amit ^b   Hahn, Stephen M ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; CD137 LIGAND; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GALECTIN 1; PROGRAMMED DEATH 1 RECEPTOR;

APOPTOSIS; ARTICLE; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REGULATORY T LYMPHOCYTE; TUMOR MICROENVIRONMENT; ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; METABOLISM; RADIATION RESPONSE;

ANIMALS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; GALECTIN 1; HUMANS; LUNG NEOPLASMS; LYMPHOPENIA;

EID: 84919628820     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2702     Document Type: Article

References (12)

1. Kuo P, Bratman SV, Shultz DB, von Eyben R, Chan C, Wang Z, et al. Galectin-1 mediates radiation-related lymphopenia and attenuates NSCLC radiation response. Clin Cancer Res 2014;20:5558-69.
2. +memory B cells through altering balances in Bcl-2 family proteins. J Immunol 2009;182: 1490-9.
3. Tang C, Liao Z, Gomez D, Levy L, Zhuang Y, Gebremichael RA, et al. Lymphopenia association with gross tumor volume and lung V5 and its effects on non -small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys 2014;89:1084-91.
4. Chakravarty PK, Alfieri A, Thomas EK, Beri V, Tanaka KE, Vikram B, et al. Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. Cancer Res 1999;59:6028-32.
5. +T cells: changing strategies for cancer treatment. Blood 2009;114:589-95.
6. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 2013;105:256-65.
7. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
8. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
9. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
10. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012;366:925-31.
11. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008;26:5233-9.
12. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33.